Human Acellular Vessel (HAV)

BIOLOGICAL3 trials

Sponsors

Humacyte, Inc.

Conditions

End Stage Renal DiseaseHemodialysisPeripheral Artery DiseaseRenal FailureVascular Access

Phase 2

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

CompletedNCT02887859

Humacyte, Inc.Peripheral Artery Disease

Start: 2016-12-20End: 2023-12-31Updated: 2025-04-18

Phase 3

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

CompletedNCT02644941

Humacyte, Inc.End Stage Renal Disease, Hemodialysis, Renal Failure +1

Start: 2016-05-24End: 2023-09-01Updated: 2026-08-19

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

CompletedNCT03183245

Humacyte, Inc.End Stage Renal Disease, Hemodialysis, Renal Failure +1

Start: 2017-09-29End: 2025-06-19Updated: 2025-11-20

Related Papers

Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts.

2023-07-147 citations

Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access.

2022-01-1015 citations